These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1087 related articles for article (PubMed ID: 14688039)

  • 1. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
    Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
    J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts.
    Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K
    Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
    Swinne D; Watelle M; Van der Flaes M; Nolard N
    Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species.
    Ramírez M; Serrano MC; Castro C; López E; Almeida C; Fernández A; Romero A; Martín-Mazuelos E
    J Antimicrob Chemother; 2006 Oct; 58(4):861-3. PubMed ID: 16916868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
    Fleck R; Dietz A; Hof H
    J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of voriconazole against Candida species isolated in Taiwan.
    Yang YL; Cheng HH; Lo HJ
    Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003.
    Cuenca-Estrella M; Rodriguez D; Almirante B; Morgan J; Planes AM; Almela M; Mensa J; Sanchez F; Ayats J; Gimenez M; Salvado M; Warnock DW; Pahissa A; Rodriguez-Tudela JL;
    J Antimicrob Chemother; 2005 Feb; 55(2):194-9. PubMed ID: 15618284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal susceptibility of bloodstream yeasts isolated at a public children's hospital in Brazil: comparison of the Etest and the AFST-EUCAST microdilution method.
    Matsumoto FE; Dias AL; Melhem MS; Szeszs MW; Auler ME; Ruiz LS; Gonçalves da Silva E; Gandra RF; Paula CR
    Can J Microbiol; 2007 Dec; 53(12):1300-6. PubMed ID: 18059562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
    Ozcan SK; Mutlu B; Dündar D; Willke A
    Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
    Seifert H; Aurbach U; Stefanik D; Cornely O
    Antimicrob Agents Chemother; 2007 May; 51(5):1818-21. PubMed ID: 17307977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
    Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
    Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
    Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
    Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005.
    Borg-von Zepelin M; Kunz L; Rüchel R; Reichard U; Weig M; Gross U
    J Antimicrob Chemother; 2007 Aug; 60(2):424-8. PubMed ID: 17562683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2006 Oct; 44(10):3533-8. PubMed ID: 17021079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.